Compound Evidence File
#EC-2026-0480
Test Suspension
Filed under Injectable Oils. The bureau holds 122 laboratory returns for this compound from 48 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
48 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 10.0 | 9.9 | 10.0 | 20 Apr 2026 | 24 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 10.0 | 10.0 | 10.0 | 4 Apr 2026 | 23 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 10.0 | 10.0 | 10.0 | 13 Feb 2026 | 5 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 10.0 | 9.9 | 10.0 | 9 Apr 2026 | 11 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 21 Mar 2026 | 14 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 10.0 | 10.0 | 10.0 | 2 Jan 2026 | 21 Apr 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 10.0 | 10.0 | 10.0 | 5 May 2026 | 16 May 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 10.0 | 10.0 | 10.0 | 25 Dec 2025 | 17 Mar 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 10.0 | 10.0 | 10.0 | 24 Jan 2026 | 13 Apr 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 1 May 2026 | 3 Jun 2026 |
| Shandong Shengyuan Peptide TechnologyCASE #VI-2026-0634 | X | 1 | 10.0 | 10.0 | 10.0 | 16 Mar 2025 | 16 Mar 2025 |
| Risynth BioCASE #VI-2026-0672 | X | 1 | 10.0 | 10.0 | 10.0 | 20 Jun 2025 | 20 Jun 2025 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 9.9 | 9.9 | 10.0 | 11 Dec 2025 | 19 May 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 10.0 | 11 Jun 2026 | 20 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 10.0 | 6 Mar 2026 | 15 Jun 2026 |
| Peptide PartnersCASE #VI-2026-0295 | X | 2 | 9.4 | 8.9 | 10.0 | 11 Jun 2025 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 4 | 8.5 | 7.5 | 9.0 | 24 May 2026 | 24 May 2026 |
| Nuscience PeptidesCASE #VI-2026-0554 | X | 2 | 8.4 | 7.5 | 9.4 | 11 Jun 2025 | 25 May 2026 |
| PeptiSlimCASE #VI-2026-0557 | X | 2 | 8.3 | 8.1 | 8.5 | 20 Jun 2025 | 17 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 4 | 8.2 | 7.4 | 9.2 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 4 | 8.2 | 7.4 | 10.0 | 24 May 2026 | 24 May 2026 |
| LiliPeptideCASE #VI-2026-0695 | X | 2 | 8.2 | 7.9 | 8.4 | 2 Jul 2025 | 17 May 2026 |
| Accelerate LabsCASE #VI-2026-0686 | X | 1 | 8.2 | 8.2 | 8.2 | 13 Jun 2025 | 13 Jun 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 7 | 7.8 | 6.6 | 10.0 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 7.8 | 7.1 | 8.5 | 24 May 2026 | 24 May 2026 |
| Lisa BiopeptideCASE #VI-2026-0131 | X | 1 | 7.8 | 7.8 | 7.8 | 9 Jun 2025 | 9 Jun 2025 |
| Welon Peptide SolutionsCASE #VI-2026-0478 | X | 1 | 7.6 | 7.6 | 7.6 | 27 Feb 2025 | 27 Feb 2025 |
| Planet PeptideCASE #VI-2026-0092 | X | 5 | 7.5 | 6.4 | 8.5 | 14 Jan 2025 | 23 May 2026 |
| PeptiAtlasCASE #VI-2026-0739 | X | 1 | 6.9 | 6.9 | 6.9 | 20 Jun 2025 | 20 Jun 2025 |
| Heman Peptide HMCASE #VI-2026-0089 | X | 2 | 6.8 | 6.5 | 7.0 | 8 Jul 2025 | 21 May 2026 |
| HXNetCASE #VI-2026-0061 | X | 9 | 6.6 | 4.6 | 9.5 | 6 May 2025 | 26 Jan 2026 |
| Zztai PeptideCASE #VI-2026-0192 | X | 1 | 6.6 | 6.6 | 6.6 | 16 Mar 2025 | 16 Mar 2025 |
| Eros PeptidesCASE #VI-2026-0918 | X | 1 | 6.6 | 6.6 | 6.6 | 25 Apr 2025 | 25 Apr 2025 |
| UWA Elite PeptidesCASE #VI-2026-0130 | X | 1 | 6.3 | 6.3 | 6.3 | 8 Jul 2025 | 8 Jul 2025 |
| ZZQ PeptidesCASE #VI-2026-0550 | X | 1 | 6.2 | 6.2 | 6.2 | 6 May 2025 | 6 May 2025 |
| Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498 | E | 3 | 6.0 | 3.9 | 7.6 | 17 Dec 2024 | 17 May 2026 |
| Paramount PeptidesCASE #VI-2026-0550 | X | 4 | 6.0 | 5.2 | 7.0 | 24 Apr 2025 | 23 May 2026 |
| SRY LabsCASE #VI-2026-0657 | X | 2 | 6.0 | 4.1 | 8.0 | 6 May 2025 | 21 May 2026 |
| Dankang BioHealthCASE #VI-2026-0775 | X | 1 | 5.7 | 5.7 | 5.7 | 8 Jul 2025 | 8 Jul 2025 |
| HealthTide BiotechCASE #VI-2026-0955 | X | 1 | 5.4 | 5.4 | 5.4 | 13 Feb 2025 | 13 Feb 2025 |
| Yabang PeptideCASE #VI-2026-0148 | X | 1 | 5.4 | 5.4 | 5.4 | 9 Jun 2025 | 9 Jun 2025 |
| Anlv BiotechnologyCASE #VI-2026-0110 | X | 1 | 5.2 | 5.2 | 5.2 | 13 Jun 2025 | 13 Jun 2025 |
| TydesCASE #VI-2026-0493 | X | 3 | 5.0 | 3.9 | 5.7 | 20 Jun 2025 | 20 May 2026 |
| Dragon PharmaCASE #VI-2026-0519 | X | 1 | 4.8 | 4.8 | 4.8 | 28 Mar 2025 | 28 Mar 2025 |
| Changan District Sheng Peptide TradingCASE #VI-2026-0341 | X | 1 | 3.3 | 3.3 | 3.3 | 11 Jun 2025 | 11 Jun 2025 |
| NuLife PeptidesCASE #VI-2026-0980 | X | 1 | 0.0 | 0.0 | 0.0 | 21 May 2025 | 21 May 2025 |
Open any subject to view the batch-level evidence for Test Suspension alone.